<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868166</url>
  </required_header>
  <id_info>
    <org_study_id>TRO19622 CL E Q 1015-1</org_study_id>
    <secondary_id>EudraCT Number:2008-007320-25</secondary_id>
    <nct_id>NCT00868166</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>MITOTARGET</acronym>
  <official_title>Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trophos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Trophos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the assay is to assess the safety and the efficacy of TRO19622 330 mg QD as
      add-on therapy to riluzole 50 mg bid in the treatment of patients suffering from ALS, as
      compared to placebo, assessed by the 18-month survival rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A stand alone treatment with TRO19622 is not acceptable for ethical reasons. Riluzole is an
      approved and widely used ALS treatment in the European community, in Japan and in the USA.

      Therefore, in this study, TRO19622 will be assessed as add-on to riluzole in patients
      suffering from ALS.

      At the start of the study, patients will be randomized to one of two groups : TRO19622 (330
      mg QD or placebo (once a day).

      Each treatment will be administered for 18 months under double-blind conditions. The product
      under evaluation will be administered to patients receiving the standard of care for ALS,
      including riluzole.

      Riluzole dosage (50 mg bid) must be stable and well tolerated for at least one month prior to
      inclusion into the study.

      After the double-blind period, open-label administration of TRO19622 will be allowed for
      safety and survival assessments and until efficacy results are available.

      A separate open-label protocol will be written 6 months after the randomization of the last
      patient into the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure will be the overall 18-month survival rate.</measure>
    <time_frame>Survival will be calculated from the date of randomization until the date of death or last follow-up censored at 18 months (548 days).</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival without occurrence of tracheostomy, chronic IV or NIV defined as &gt;23h of NIV daily for 14 consecutive days.</measure>
    <time_frame>Time to failure will be defined as the time from randomization to the time of the first event to consider (Tracheostomy, IV or NIV)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score of the 48-point ALS Functional Rating Scale Revised, with a focus on the 9-month assessment</measure>
    <time_frame>Inclusion, Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Vital Capacity (SVC) as a percentage of predicted SVC and survival with SVC &gt;50%</measure>
    <time_frame>Screening, Inclusion, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Score of Manual Muscle Testing of 34 muscle groups</measure>
    <time_frame>Inclusion, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The single-item Mc Gill Quality of life scale</measure>
    <time_frame>Inclusion, Month 1, Month 3, Month 6, Month 9, Month 12, Month 15 and Month 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">512</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>TRO19622</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 Capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzole 50mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 Capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olesoxime</intervention_name>
    <description>2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid</description>
    <arm_group_label>TRO19622</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with sporadic or familial Amyotrophic Lateral Sclerosis

          -  Patients with a clinical diagnosis of laboratory-supported probable, probable, or
             definite ALS according to the modified El Escorial criteria8.

          -  Have signed an Informed Consent to participate to the trial before any study related
             procedure has taken place.

          -  Be of age &gt;18 (exclusive) and &lt; 80 years (inclusive).

          -  If a female, not lactating, has a negative pregnancy test and agrees to use an
             effective method of birth control.

          -  Onset of ALS Symptoms (weakness) for more than 6 months (inclusive) and less than 36
             months(inclusive).

          -  Slow vital capacity (SVC), measured three times, one of the measure being &gt;/= 70% of
             that predicted.

          -  Treated with riluzole at the stable dose of 50 mg bid for at least 30 days before
             enrolment.

        Exclusion Criteria:

          -  Tracheostomy, invasive ventilation, or non invasive positive pressure ventilation
             (NIPPV).

          -  Gastrostomy.

          -  Evidence of major psychiatric disorder or clinically evident dementia.

          -  Diagnosis of a neurodegenerative disease in addition to ALS.

          -  Have a current medication that could interfere with TRO19622 pharmacokinetics:
             tamoxifene.

          -  Have current medications that could interfere with TRO19622 absorption such as
             ezetimibe, bile salts chelators (cholesteramine), fibrates, phytosterols, niacin
             (vitamin B3),fish oils. Have a current medication of lipid lowering agents other than
             statins.

          -  Known hypersensitivity to any component of the study drug.

          -  Patients with known intolerance or contra-indication to riluzole.

          -  Have a recent history (within the previous 6 months) or current evidence of alcohol or
             drug abuse.

          -  Have concurrent unstable disease involving any system eg, carcinoma other than basal
             cell carcinoma, any cardiac dysrhythmia, myocardial infarction, clinical or ECG signs
             of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms of
             Coronary Artery Disease, or any other condition that in the opinion of the
             Investigator would make the patient unsuitable for study participation.

             . In Germany: Have any cardiac dysrhythmia, myocardial infarction, clinical or ECG
             signs of myocardial ischemia, cardiac insufficiency, angina symptoms, current symptoms
             of Coronary Artery Disease or any cardiovascular illness known or identified at the
             screening or inclusion visits, or have concurrent unstable disease involving any
             system eg, carcinoma other than basal cell carcinoma or any other condition that in
             the opinion of the Investigator would make the patient unsuitable for study
             participation.

          -  Having a baseline QTc (Bazett) &gt; 450 msec for males and &gt; 470 msec for females.

          -  Patients with known hepatitis B/C or HIV positive serology.

          -  Be pregnant female or lactating.

          -  Have renal impairment defined as blood creatinine &gt; 1:5 X upper limit of normal.

          -  Have hepatic impairment and/or liver enzymes (ALAT or ASAT) &gt; 3 X ULN.

          -  Hemostasis disorders or current treatment with oral anticoagulants.

          -  Be possibly dependent on the Investigator or the Sponsor (eg, including, but not
             limited to, affiliated employee).

          -  Participated in any other investigational drug or therapy study with a non approved
             medication, within the previous 3 months.

          -  Patients without Social Security Insurance (France).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Meininger, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe Hospitalier Pitie-Salpetriere</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg - Dept Neurology - Herestraat 49</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCL Hôpital Neurologique et Neurochirurgical Pierre Wertheimer - Neurologie C et Laboratoire d'électromyographie - 59, boulevard Pinel</name>
      <address>
        <city>Bron Cedex</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE - Hôpital Roger Salengro - Centre SLA-MMN - Sce de Neurologie et Pathologie du Mouvement</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre SLA Limoges - Service de Neurologie</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone - Service Neurologie et Maladies Neuromusculaires</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Motoneurone - Sce d'Explorations Neurologiques - Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital de l'Archet 1 - Centre de Référence pour les Maladies Neuromusculaires et la SLA</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier PITIE-SALPETRIERE - Fédération des Maladies du Système Nerveux</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Neurologische Poliklinik Ambulanz für ALS und andere Motoeneuronenerkrankungen</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik und Poliklinik für Neurologie - Martin-Luther-Universität Halle-Wittenberg</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <zip>D-30623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts- und Rehabilitationskliniken Ulm (RKU) - Neurologische Universitätsklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos III - Unidad de ELA - Sinesio Delgado, 10</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's MND Care and Research Center - Academic Neurosciences Building PO Box 41 Institute of Psychiatry</name>
      <address>
        <city>London</city>
        <zip>SE58AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Neurology Unit - University of Sheffield - Section of Neuroscience - Division of Genomic Medicine - School of Medicine and Biomedical Sciences</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2009</study_first_posted>
  <last_update_submitted>March 27, 2012</last_update_submitted>
  <last_update_submitted_qc>March 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>TRO19622</keyword>
  <keyword>Trophos</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 24, 2014</submitted>
    <returned>December 2, 2014</returned>
    <submitted>November 21, 2016</submitted>
    <returned>January 13, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

